Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Biosimilar Trial to Investigate PK, PD, Safety With PB018 Versus US-licensed Ocrevus and EU-approved Ocrevus
Sponsor: Polpharma Biologics International AG
Summary
This is a randomized, parallel group, double-blind, active-controlled, clinical pharmacology study to compare Pharmacokinetics, Pharmacodynamics and safety of PB018 versus Ocrevus in patients with Multiple Sclerosis.
Official title: A Randomized, Parallel-Group Double-Blind, Biosimilar Trial to Compare Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of PB018 Versus Ocrevus® in Participants With Multiple Sclerosis (MS)
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
222
Start Date
2026-10
Completion Date
2028-04
Last Updated
2026-05-28
Healthy Volunteers
No
Conditions
Interventions
US-Ocrevus
Intravenous(IV) infusion
PB018
Intravenous(IV) infusion
EU-Ocrevus
Intravenous(IV) infusion